European journal of clinical investigation
-
Eur. J. Clin. Invest. · Mar 2008
Randomized Controlled Trial Multicenter StudyImprovement of glycaemic control by nateglinide decreases systolic blood pressure in drug-naive patients with type 2 diabetes.
It has been speculated that oral hypoglycaemic agents that block K-ATP channels could potentially increase blood pressure by blocking such channels in vascular myocytes. No information about this issue exists regarding nateglinide. ⋯ In drug-naive patients with type 2 diabetes, the improvement in glycaemic control with nateglinide is associated with a decrease in systolic blood pressure.